Reuters logo
BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated
March 17, 2017 / 12:53 PM / in 9 months

BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated

March 17 (Reuters) - Eli Lilly And Co

* First dedicated outcome trials of Empagliflozin in chronic heart failure initiated

* Emperor HF comprises two phase III outcome studies that will investigate empagliflozin for treatment of adults with chronic heart failure

* Trials will involve not only adults with type 2 diabetes who have heart failure, but also heart failure patients who do not have diabetes

* Emperor HF’s two trials will involve approximately 7,000 patients in total and are anticipated to complete in 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below